Stay updated with breaking news from Gil Roth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Swiss contract manufacturer’s cash deal for Roche’s Genentech facility in Vacaville, California, is one of the world’s largest manufacturing sites for biologics—a major growth driver for Lonza and other CDMOs.
As the landscape of healthcare continues to evolve, so too does the field of drug delivery.
Novo Nordisk recently acquired three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.
While analysts are bullish on Novo Holdings’ $16.5 billion acquisition of Catalent, they say it raises questions for companies that have contracted the CDMO for manufacturing.
BioSpace spoke to analysts and players in the contract manufacturing and development organizations space to assess the challenges this year and what lies ahead in 2024.